RCMI Coordinating Center (RCMI CC) Header Logo

Connection

LaMonica Stewart to Prostatic Neoplasms

This is a "connection" page, showing publications LaMonica Stewart has written about Prostatic Neoplasms.
Connection Strength

1.394
  1. Olokpa E, Bolden A, Stewart LV. The Androgen Receptor Regulates PPAR? Expression and Activity in Human Prostate Cancer Cells. J Cell Physiol. 2016 12; 231(12):2664-72.
    View in: PubMed
    Score: 0.285
  2. Akinyeke TO, Stewart LV. Troglitazone suppresses c-Myc levels in human prostate cancer cells via a PPAR?-independent mechanism. Cancer Biol Ther. 2011 Jun 15; 11(12):1046-58.
    View in: PubMed
    Score: 0.205
  3. Moss PE, Lyles BE, Stewart LV. The PPAR? ligand ciglitazone regulates androgen receptor activation differently in androgen-dependent versus androgen-independent human prostate cancer cells. Exp Cell Res. 2010 Dec 10; 316(20):3478-88.
    View in: PubMed
    Score: 0.196
  4. Lyles BE, Akinyeke TO, Moss PE, Stewart LV. Thiazolidinediones regulate expression of cell cycle proteins in human prostate cancer cells via PPARgamma-dependent and PPARgamma-independent pathways. Cell Cycle. 2009 Jan 15; 8(2):268-77.
    View in: PubMed
    Score: 0.173
  5. Stewart LV, Lyles B, Lin MF, Weigel NL. Vitamin D receptor agonists induce prostatic acid phosphatase to reduce cell growth and HER-2 signaling in LNCaP-derived human prostate cancer cells. J Steroid Biochem Mol Biol. 2005 Oct; 97(1-2):37-46.
    View in: PubMed
    Score: 0.136
  6. Stewart LV, Weigel NL. Role of insulin-like growth factor binding proteins in 1alpha,25-dihydroxyvitamin D(3)-induced growth inhibition of human prostate cancer cells. Prostate. 2005 Jun 15; 64(1):9-19.
    View in: PubMed
    Score: 0.135
  7. Stewart LV, Weigel NL. Vitamin D and prostate cancer. Exp Biol Med (Maywood). 2004 Apr; 229(4):277-84.
    View in: PubMed
    Score: 0.124
  8. Swamy N, Chen TC, Peleg S, Dhawan P, Christakos S, Stewart LV, Weigel NL, Mehta RG, Holick MF, Ray R. Inhibition of proliferation and induction of apoptosis by 25-hydroxyvitamin D3-3beta-(2)-Bromoacetate, a nontoxic and vitamin D receptor-alkylating analog of 25-hydroxyvitamin D3 in prostate cancer cells. Clin Cancer Res. 2004 Dec 01; 10(23):8018-27.
    View in: PubMed
    Score: 0.033
  9. Brown LK, Kanagasabai T, Li G, Celada SI, Rumph JT, Adunyah SE, Stewart LV, Chen Z. Co-targeting SKP2 and KDM5B inhibits prostate cancer progression by abrogating AKT signaling with induction of senescence and apoptosis. Prostate. 2024 Jun; 84(9):877-887.
    View in: PubMed
    Score: 0.031
  10. Polek TC, Stewart LV, Ryu EJ, Cohen MB, Allegretto EA, Weigel NL. p53 Is required for 1,25-dihydroxyvitamin D3-induced G0 arrest but is not required for G1 accumulation or apoptosis of LNCaP prostate cancer cells. Endocrinology. 2003 Jan; 144(1):50-60.
    View in: PubMed
    Score: 0.029
  11. Blutt SE, Polek TC, Stewart LV, Kattan MW, Weigel NL. A calcitriol analogue, EB1089, inhibits the growth of LNCaP tumors in nude mice. Cancer Res. 2000 Feb 15; 60(4):779-82.
    View in: PubMed
    Score: 0.023
  12. Tang B, de Castro K, Barnes HE, Parks WT, Stewart L, B?ttinger EP, Danielpour D, Wakefield LM. Loss of responsiveness to transforming growth factor beta induces malignant transformation of nontumorigenic rat prostate epithelial cells. Cancer Res. 1999 Oct 01; 59(19):4834-42.
    View in: PubMed
    Score: 0.023
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support